On April 15, 2025, the White House announced a new executive order aimed at reducing prescription drug prices in the United States.

This order highlights the necessity of reviving progress from previous initiatives that sought to make medications more affordable for American patients, particularly those enrolled in Medicare. Key features of the plan include enhancements to the Medicare Drug Price Negotiation Program, increased transparency in drug pricing, and addressing the role of intermediaries in the pharmaceutical supply chain.

The order outlines various actions to be implemented within specific time frames, such as proposing guidance for the Medicare Drug Price Negotiation Program and providing recommendations to stabilize Medicare Part D premiums. Additionally, it aims to expedite the approval process for generic and biosimilar medications, foster competition in drug pricing, and simplify the importation of lower-cost drugs. The overarching goal is to ensure that federal health care programs and regulations promote better access to affordable prescription drugs for all Americans.

This initiative is a response to identified shortcomings in previous drug pricing reforms and represents a commitment to prioritize the health and financial well-being of Americans. The administration encourages collaboration with Congress to develop sustainable solutions for drug pricing while fostering innovation in the pharmaceutical sector. By addressing these issues, the White House aims to increase the affordability and accessibility of essential medications for American patients.

Original: article